Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Akari Therapeutics (AKTX)

Akari Therapeutics (AKTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,488
  • Shares Outstanding, K 15,857
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,470 K
  • 60-Month Beta -2.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 0.00
  • Number of Estimates 1
  • High Estimate 0.00
  • Low Estimate 0.00
  • Prior Year -0.04
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.65 +5.45%
on 09/27/19
2.15 -19.07%
on 10/09/19
-0.15 (-7.94%)
since 09/23/19
3-Month
1.61 +7.79%
on 08/27/19
3.35 -48.06%
on 08/14/19
-0.29 (-14.29%)
since 07/23/19
52-Week
1.56 +11.54%
on 12/31/18
9.20 -81.09%
on 03/14/19
-0.06 (-3.33%)
since 10/23/18

Most Recent Stories

More News
Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I/II AKC Trial

-- Biopsy tissue expresses the complement C5a receptor 1 and the leukotriene LTB4 receptor BLT1 on and within the surface of the eye, a previously unreported finding

AKTX : 1.74 (+2.35%)
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress

-- Treatment with nomacopan in six patients in Phase II trial was well tolerated and resulted in rapid onset of clinical improvement in five of six patients

AKTX : 1.74 (+2.35%)
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...

AKTX : 1.74 (+2.35%)
Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease

The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.

ACOR : 2.70 (+11.78%)
ALXN : 106.63 (+7.40%)
EMMA : 2.4200 (-8.68%)
AKTX : 1.74 (+2.35%)
Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...

AKTX : 1.74 (+2.35%)
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More

Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.

SNY : 45.77 (+0.99%)
REGN : 305.02 (+1.23%)
AMGN : 203.32 (-0.74%)
VRTX : 190.51 (-0.29%)
FATE : 14.80 (+0.61%)
ARDX : 4.96 (-1.20%)
AKTX : 1.74 (+2.35%)
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...

AKTX : 1.74 (+2.35%)
Akari's Nomacopan Gets Orphan Drug Tag for Rare Disease

The FDA assigns an orphan drug status to Akari's (AKTX) nomacopan for the treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy, which is a rare disease.

NCNA : 7.25 (+3.57%)
AKTX : 1.74 (+2.35%)
REXN : 1.85 (-3.65%)
EMMA : 2.4200 (-8.68%)
Thinking about buying stock in Aurora Cannabis, Akari Therapeutics, Big Lots, Campbell Soup, or Walt Disney Co?

InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, BIG, CPB, and DIS.

AKTX : 1.74 (+2.35%)
ACB.TO : 4.82 (+2.77%)
BIG : 22.13 (+8.80%)
CPB : 47.80 (+0.27%)
DIS : 131.13 (-0.96%)
Akari Therapeutics' Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene...

AKTX : 1.74 (+2.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade AKTX with:

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

2nd Resistance Point 1.77
1st Resistance Point 1.76
Last Price 1.74
1st Support Level 1.71
2nd Support Level 1.67

See More

52-Week High 9.20
Fibonacci 61.8% 6.28
Fibonacci 50% 5.38
Fibonacci 38.2% 4.48
Last Price 1.74
52-Week Low 1.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar